To determine if a scheduled administrated of simethicone and metoclopramide as part of routine postoperative pain management regimens following cesarean delivery can decrease patient need for opiate analgesia following cesarean delivery. STUDY DESIGN: We conducted a prospective observational cohort study and followed all women receiving scheduled administrated of simethicone and metoclopramide as part of routine postoperative pain management regimens following cesarean delivery. These patients were compared to matched controls who did not receive scheduled administration of these drugs. Both groups received the same postoperative pain management regimen which included acetaminophen 1000mg PO every 6 hours, ketorolac 30mg IV for 8 doses followed by ibuprofen 600mg PO every 6 hours, and oxycodone 5mg PO every 6 hours as needed for moderate pain and 10mg PO every 6 hours as needed for severe pain. The control group was ordered for ondansetron 4mg IV as needed for nausea whereas the simethicone/metoclopramide group received metoclopramide 10mg IV every 6 hours. Simethicone was ordered as 160mg PO every 6 hours for the intervention group. Inclusion criteria included patients with pfannestiel surgical incisions and low transverse cesarean deliveries. Patients were excluded if they required a vertical skin incision, a classical cesarean delivery, and/or additional procedures intraoperatively at time of cesarean delivery. RESULTS: The study included 88 patients, with 44 patients in each arm. When compared with the control regimen group, the simethicone/metoclopramide regimen group had lower rates of opiate use 39.9% (95% CI 31.7-45.4) versus 46.8% (95% CI 41.1-49.0), p ¼ 0.013. The simethicone/metoclopramide group also demonstrated a decreased length of hospital stay when compared with the control group with an average hospital stay of 3.1AE0.5 (2-4) versus 3.9AE0.8 (2-6), p ¼ 0.001. After adjusting for BMI, diabetes mellitus, gestational blood pressure >140/90, group b-Streptococcus status, race, advanced maternal age (>34 y), and parity, this difference was still preserved for lower opiate use and decreased hospital stay, p ¼ 0.02 and p ¼ 0.05 respectively. There was no difference in rates of postoperative ileus or small bowel obstruction. CONCLUSION: By simply administering scheduled dosing of simethicone and metoclopramide following cesarean deliveries, the use of opiates and extended postoperative hospital stays can potentially be mitigated.
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